Lonza Group AG stock (CH0013841017): shares slightly higher in Zurich after recent earnings update

Lonza Group AG shares traded modestly higher on SIX Swiss Exchange on Tuesday as investors in Switzerland continued to react to the company’s latest quarterly results and guidance in the biopharma services market.

Lonza Group AG shares traded slightly firmer on the SIX Swiss Exchange in Zurich on Tuesday, with the stock edging higher in Swiss franc trading as investors in Switzerland continued to digest the company’s latest quarterly earnings and outlook for its contract development and manufacturing business, according to Reuters as of 05/14/2026. The move comes after the Basel-based biopharma services group reported its most recent results and updated its mid-term expectations, keeping the stock in focus on its home market.

The stock traded at around CHF 470 on 05/14/2026 on SIX Swiss Exchange, according to data cited by Reuters as of 05/14/2026. In Switzerland, the shares continue to be a key component of the domestic healthcare and life sciences segment, with liquidity centered on the Swiss blue-chip venue. For German investors, the stock is also accessible via trading venues such as Tradegate, where prices are quoted in euro based on the underlying Swiss franc listing.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Lonza
• Sector/industry: Biopharmaceutical contract development and manufacturing
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, North America and Asia for outsourced biopharma services
• Key revenue drivers: Biologic drug substance manufacturing, cell and gene therapy services, and small molecule contract manufacturing
• Home exchange/listing venue: SIX Swiss Exchange (LONN)
• Trading currency: CHF

Lonza Group AG: core business model

Lonza positions itself as a specialist in outsourced biopharmaceutical manufacturing and development services, generating most of its revenue from long-term contracts to produce biologics, cell and gene therapies and other complex medicines for global pharmaceutical and biotechnology customers.

Latest quarterly results for Lonza Group AG at a glance

Lonza released its most recent quarterly figures on 04/23/2026, providing investors with an update on revenue growth, margins and project pipeline across its biologics and cell and gene therapy operations, according to the company’s earnings communication as of 04/23/2026. The group reported sales growth in line with its strategy to focus on high-value development and manufacturing projects, while reiterating key elements of its mid-term guidance for the biopharma services portfolio.

Management also commented on capacity utilization trends in its major facilities and on demand from large pharmaceutical clients and emerging biotech firms, highlighting continued interest in biologics and advanced therapies under longer-term supply agreements, according to the same 04/23/2026 update. For investors on SIX Swiss Exchange, these quarterly figures and the accompanying guidance remain a central reference point when assessing the stock’s performance in the Swiss market.

Conclusion

The modestly higher share price for Lonza Group AG on SIX Swiss Exchange on Tuesday keeps attention on the Swiss group’s recent quarterly update and its role in the global biopharma services market. With investors in Switzerland watching how management executes on capacity and margin plans outlined on 04/23/2026, the stock remains closely tied to developments in biologics and advanced therapy demand.

As the company continues to report earnings and refine its guidance, market participants will monitor whether order momentum and utilization trends support the valuation currently implied by trading in Zurich and on German venues such as Tradegate, without this article expressing any view on future price performance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.